Efficacy
disease shrinkage
DISEASE PROGRESSION, DISEASE
Four out of the five patients on the study had measurable disease as defined by RECIST 1.1 at the time of enrollment. The patient without measurable disease discontinued study therapy early due to poor tolerance. The patient did not have a disease assessment while on study, and therefore was excluded from all efficacy analyses except overall survival. On average, patients completed 4 cycles of therapy with a range from 2 to 6 cycles. However, at the time of study discontinuation, one subject transferred over to an expanded access program and received an additional 4 cycles of the combination, receiving a total of 6 cycles of study therapy.Three of the four patients with measurable disease achieved stable disease with disease shrinkage on scans while on study therapy, two of these had previously progressed on pembrolizumab. One patient had disease progression without any appreciable response. As shown in Fig. 
Response to treatment with pembrolizumab + rivoceranib. Kaplan-Meier Curves demonstrating 